Skip to main content
55°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Today 7:00 EST
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
October 15, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
September 04, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
August 08, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
June 28, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
June 12, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
May 09, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
May 08, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
April 11, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
February 26, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DNTH
Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 23, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference
January 31, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces $230 Million Private Placement
January 22, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer
November 29, 2023
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results
November 09, 2023
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate in Upcoming Investor Healthcare Conferences in November
November 01, 2023
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH
September 12, 2023
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split
September 11, 2023
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.